<p>Hyderabad-based drugmaker Biological E's Corbevax has become the first vaccine in India to get the Drugs Controller General of India's (DCGI) approval for a heterologous COVID-19 booster shot.</p>

<p>According to Biological E, people who are 18 years and above as well as who have already taken two doses of either Covishield or Covaxin can now receive a dose of Corbevax.</p>

<p>Earlier, a government panel had also recommended granting emergency use authorisation for Corbevax for children in the five to 11 years age group.</p>

<p>“The Subject Expert Committee on COVID-19 of the CDSCO which deliberated on Biological E’s EUA application has recommended granting emergency use authorisation for use of Corbevax in the age group of five to 11 years,” a source told news agency PTI.</p>

<div class="videoWrapper trancodeVideo"><iframe allowfullscreen="" autoplay="1" class="includeVideo" frameborder="0" height="350" src="https://www.wionews.com/videos/who-admits-to-making-another-mistake-and-is-recalculating-the-official-covid-19-death-toll-484881/embed" style="width:100%;max-width:560px;" width="560"></iframe></div>

<p>"The BE's Corbevax is the first such vaccine in India to be approved as a heterologous COVID-19 booster. Recently, BE has furnished its clinical trials data to the DCGI who after a detailed evaluation and deliberations with the Subject Experts Committee granted their approval for administering the Corbevax vaccine as a heterologous booster dose to people who have already taken two doses of either Covishield or Covaxin," a statement issued by pharmaceutical and vaccines company read.</p>

<p>Mahima Datla, Managing Director, Biological E. Limited, said, "We are very happy with this approval, which will address the need for COVID-19 booster doses in India. We have crossed yet another milestone in our COVID-19 vaccination journey. This approval reflects once again the sustained world-class safety standards and high immunogenicity of Corbevax."</p>

<p><strong>Also read |&nbsp;<a href="https://www.wionews.com/india-news/covid-19-indian-govt-suspects-possibility-of-localised-spread-of-infection-writes-to-five-states-484937" hreflang="en">Covid-19: Indian govt suspects possibility of localised spread of infection</a></strong></p>

<p>The statement further said, "Biological E has conducted a multicentre Phase III placebo-controlled heterologous booster clinical trial in 416 subjects from 18 to 80 years of age who were previously vaccinated with two doses of either Covishield or Covaxin at least 6 months prior to the administration of CORBEVAX as a booster dose."</p>

<p>"In a subset of subjects evaluated for nAb against the Omicron variant, the Corbevax booster shot resulted in a significant increase in the nAb titers against the Omicron variant. After the booster dose of Corbevax, Omicron nAbs were observed in 91 pc and 75 pc of subjects who had received primary vaccination by Covishield and Covaxin respectively," said the statement.</p>

<p>India began administering precaution doses of vaccines to healthcare and frontline workers and those aged 60 and above with comorbidities from January 10.</p>

<p><em>(With inputs from agencies)</em></p>

<p><strong>Watch WION's live TV here:</strong></p>

<div class="ui-state-default" contenteditable="false">
<div class="twitter-block" draggable="false"><iframe allow="accelerometer; autoplay; encrypted-media; gyroscope; picture-in-picture" allowfullscreen="" frameborder="0" height="350" src="https://www.wionews.com/live-tv/embed?autoplay=1&amp;mute=1">&amp;times;</iframe></div>

<p>&nbsp;</p>
</div>


Hyderabad-based drugmaker Biological E's Corbevax has become the first vaccine in India to get the Drugs Controller General of India's (DCGI) approval for a heterologous COVID-19 booster shot.

Hyderabad-based drugmaker Biological E's Corbevax has become the first vaccine in India to get the Drugs Controller General of India's (DCGI) approval for a heterologous COVID-19 booster shot. According to Biological E, people who are 18 years and above as well as who have already taken two doses of either Covishield or Covaxin can now receive a dose of Corbevax. Earlier, a government panel had also recommended granting emergency use authorisation for Corbevax for children in the five to 11 years age group. “The Subject Expert Committee on COVID-19 of the CDSCO which deliberated on Biological E’s EUA application has recommended granting emergency use authorisation for use of Corbevax in the age group of five to 11 years,” a source told news agency PTI. "The BE's Corbevax is the first such vaccine in India to be approved as a heterologous COVID-19 booster. Recently, BE has furnished its clinical trials data to the DCGI who after a detailed evaluation and deliberations with the Subject Experts Committee granted their approval for administering the Corbevax vaccine as a heterologous booster dose to people who have already taken two doses of either Covishield or Covaxin," a statement issued by pharmaceutical and vaccines company read. Mahima Datla, Managing Director, Biological E. Limited, said, "We are very happy with this approval, which will address the need for COVID-19 booster doses in India. We have crossed yet another milestone in our COVID-19 vaccination journey. This approval reflects once again the sustained world-class safety standards and high immunogenicity of Corbevax." Also read | Covid-19: Indian govt suspects possibility of localised spread of infection The statement further said, "Biological E has conducted a multicentre Phase III placebo-controlled heterologous booster clinical trial in 416 subjects from 18 to 80 years of age who were previously vaccinated with two doses of either Covishield or Covaxin at least 6 months prior to the administration of CORBEVAX as a booster dose." "In a subset of subjects evaluated for nAb against the Omicron variant, the Corbevax booster shot resulted in a significant increase in the nAb titers against the Omicron variant. After the booster dose of Corbevax, Omicron nAbs were observed in 91 pc and 75 pc of subjects who had received primary vaccination by Covishield and Covaxin respectively," said the statement. India began administering precaution doses of vaccines to healthcare and frontline workers and those aged 60 and above with comorbidities from January 10. (With inputs from agencies) Watch WION's live TV here:

Corbevax becomes first vaccine in India to get DCGI approval for heterologous COVID-19 booster shot

<p>Novavax announced on Tuesday (March 22) that the Drugs Controller General of India (DCGI) has granted its coronavirus (COVID-19) vaccine emergency-use authorisation for children aged 12 to 17 years.&nbsp;</p>

<p>In a statement published on its website, the company noted that DCGI has granted emergency use authorisation (EUA) for Novavax jabs for adolescents.&nbsp;</p>

<p>"The vaccine, also known as NVX-CoV2373, is manufactured and marketed in India by SII [Serum Institute of India Pvt. Ltd.] under the brand name Covovax™ and is the first protein-based vaccine authorized for use in this age group in India," the statement read.&nbsp;</p>

<p>DCGI has issued permission for restricted use in an emergency situation for Covovax for active immunisation to prevent Covid caused by SARS-CoV-2 in individuals 12 years of age and older.</p>

<p><strong>ALSO READ |&nbsp;<a href="https://www.wionews.com/india-news/india-may-expand-covid-booster-dose-for-all-adults-reports-464345">India may expand Covid booster dose for all adults: Reports</a></strong></p>

<p>Novavax last month said its vaccine was 80 per cent effective against Covid in a late-stage trial testing the shot in 2,247 teens aged 12 to 17 years.&nbsp;</p>

<p>The country's drug regulator in December authorised Novavax's COVID-19 vaccine for people aged 18 years and above.</p>

<p>Covovax has also received Emergency Use Listing (EUL) from the World Health Organization.&nbsp;</p>

<div class="ui-state-default" contenteditable="false">
<div class="twitter-block" draggable="false">
<blockquote class="twitter-tweet">
<p dir="ltr" lang="en">Novavax and Serum Institute of India Announce First Emergency Use Authorization of Novavax' COVID-19 Vaccine in Adolescents ≥12 to &lt;18 in India: <a href="https://t.co/rYDgw9jNM0">https://t.co/rYDgw9jNM0</a></p>
— Novavax (@Novavax) <a href="https://twitter.com/Novavax/status/1506367180543344642?ref_src=twsrc%5Etfw">March 22, 2022</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
<a class="close-mark close-div" href="#" id="jqclosemark">×</a></div>

<p>Stanley C Erck, President and Chief Executive Officer, Novavax said, "We're proud of this first approval in adolescents given the efficacy and safety that our data show in this population and that our COVID-19 vaccine will provide an alternative protein-based vaccine option for individuals 12 years of age and older in India." &nbsp;</p>

<p>Adar Poonawalla, Chief Executive Officer, Serum Institute of India, "The approval of Covovax for adolescents 12 and older in India marks another significant milestone in strengthening our immunization efforts across India and LMICs."&nbsp;</p>

<p>He added, "We are proud to deliver a protein-based COVID-19 vaccine with a favourable safety profile to the adolescents of our nation."&nbsp;</p>

<p><strong>WATCH |&nbsp;Coronavirus cases surge in western Europe, France reports 90,000 average daily Covid-19 cases</strong></p>

<div class="ui-state-default" contenteditable="false">
<div class="twitter-block" draggable="false">
<div class="videoWrapper trancodeVideo"><iframe allowfullscreen="" autoplay="1" class="includeVideo" frameborder="0" height="350" src="https://www.wionews.com/videos/coronavirus-cases-surge-in-western-europe-france-reports-90000-average-daily-covid-19-cases-464734/embed" style="width:100%;max-width:560px;" width="560"></iframe></div>
</div>
<a class="close-mark close-div" href="#" id="jqclosemark">×</a></div>

<p><em>(With inputs from agencies)&nbsp;</em></p>


Novavax announced on Tuesday (March 22) that the Drugs Controller General of India (DCGI) has granted its coronavirus (COVID-19) vaccine emergency-use authorisation for children aged 12 to 17 years.

Novavax announced on Tuesday (March 22) that the Drugs Controller General of India (DCGI) has granted its coronavirus (COVID-19) vaccine emergency-use authorisation for children aged 12 to 17 years. In a statement published on its website, the company noted that DCGI has granted emergency use authorisation (EUA) for Novavax jabs for adolescents. "The vaccine, also known as NVX-CoV2373, is manufactured and marketed in India by SII [Serum Institute of India Pvt. Ltd.] under the brand name Covovax™ and is the first protein-based vaccine authorized for use in this age group in India," the statement read. DCGI has issued permission for restricted use in an emergency situation for Covovax for active immunisation to prevent Covid caused by SARS-CoV-2 in individuals 12 years of age and older. ALSO READ | India may expand Covid booster dose for all adults: Reports Novavax last month said its vaccine was 80 per cent effective against Covid in a late-stage trial testing the shot in 2,247 teens aged 12 to 17 years. The country's drug regulator in December authorised Novavax's COVID-19 vaccine for people aged 18 years and above. Covovax has also received Emergency Use Listing (EUL) from the World Health Organization. Novavax and Serum Institute of India Announce First Emergency Use Authorization of Novavax' COVID-19 Vaccine in Adolescents ≥12 to <18 in India: https://t.co/rYDgw9jNM0 — Novavax (@Novavax) March 22, 2022 × Stanley C Erck, President and Chief Executive Officer, Novavax said, "We're proud of this first approval in adolescents given the efficacy and safety that our data show in this population and that our COVID-19 vaccine will provide an alternative protein-based vaccine option for individuals 12 years of age and older in India." Adar Poonawalla, Chief Executive Officer, Serum Institute of India, "The approval of Covovax for adolescents 12 and older in India marks another significant milestone in strengthening our immunization efforts across India and LMICs." He added, "We are proud to deliver a protein-based COVID-19 vaccine with a favourable safety profile to the adolescents of our nation." WATCH | Coronavirus cases surge in western Europe, France reports 90,000 average daily Covid-19 cases × (With inputs from agencies)

Novavax says its COVID-19 vaccine gets India authorisation for children aged 12 to 17 years

<p>India's <strong>Covaxin</strong>&nbsp;has shown 77.8 per cent efficacy against coronavirus in phase 3 trial data in review by the subject expert committee, news agency ANI quoting sources reported on Tuesday.</p>

<p>According to ANI sources, Covaxin is likely to get clearance from the<strong> Drugs Controller General of India</strong> (DCGI) today.</p>

<p><strong>Watch:</strong></p>

<div class="videoWrapper trancodeVideo"><iframe allowfullscreen="" autoplay="1" class="includeVideo" frameborder="0" height="350" src="https://www.wionews.com/videos/biden-administration-announces-allocation-plan-for-55-mn-covid-19-vaccine-doses-393157/embed" style="width:100%;max-width:560px;" width="560"></iframe></div>

<p>The development comes as the health ministry said on Tuesday that the average daily <a href="https://www.wionews.com/world/abdala-vaccine-9228-effective-against-covid-19-says-cuba-393134"><strong>vaccination</strong></a> was 34,62,841 in the country, therefore 88 lakh vaccines and capacity is possible.</p>

<p>India on Monday administered <strong>88.09 lakh <a href="https://www.wionews.com/india-news/over-82-million-vaccine-doses-administered-across-india-health-ministry-393026">vaccine</a> jabs</strong> in a single day reaching a historic milestone with<strong> Madhya Pradesh</strong> inoculating the highest number of doses numbering over 17 lakh followed by Karnataka with 11 lakh doses, Uttar Pradesh with 7 lakh jabs and Bihar with 5.75 lakh doses</p>

<p>The health ministry informed that Indian vaccines <strong>Covishield </strong>and Covaxin are effective against the Delta variant.</p>

<p>Niti Aayog's&nbsp;VK Paul informed that more than half of the doses administered over the last few weeks were inoculated in <strong>rural</strong> areas.</p>

<p>Union health secretary Rajesh Bhushan informed that the new <strong>Delta Plus variant</strong> has been found in 16 of the 22 cases including Ratnagiri and Jalgaon in <strong>Maharashtra</strong> including Kerala and Madhya Pradesh.</p>

<p>As India continues to battle the virus, the health ministry announced that in 553<strong> districts</strong> in the country the coronavirus positivity rate has dipped to less than 5 per cent.</p>

<p>The ministry said that over 2.14 crore coronavirus <strong>vaccine doses </strong>were still available with the states and Union Territories and over 33,80,590 vaccine doses are in the pipeline.</p>

<p>On Monday, the Indian government had started the <strong>"Free Vaccination For All campaign"</strong>.</p>

<p>According to the revised guidelines, vaccine doses will be provided free of cost by the Centre based on criteria such as state's population, disease burden and vaccination progress. All adults above 18 years will be eligible for the <strong>free jabs</strong>.</p>


India's Covaxin has shown 77.8 per cent efficacy against coronavirus in phase 3 trial data in review by the subject expert committee, news agency ANI quoting sources reported on Tuesday.

India's Covaxin has shown 77.8 per cent efficacy against coronavirus in phase 3 trial data in review by the subject expert committee, news agency ANI quoting sources reported on Tuesday. According to ANI sources, Covaxin is likely to get clearance from the Drugs Controller General of India (DCGI) today. Watch: The development comes as the health ministry said on Tuesday that the average daily vaccination was 34,62,841 in the country, therefore 88 lakh vaccines and capacity is possible. India on Monday administered 88.09 lakh vaccine jabs in a single day reaching a historic milestone with Madhya Pradesh inoculating the highest number of doses numbering over 17 lakh followed by Karnataka with 11 lakh doses, Uttar Pradesh with 7 lakh jabs and Bihar with 5.75 lakh doses The health ministry informed that Indian vaccines Covishield and Covaxin are effective against the Delta variant. Niti Aayog's VK Paul informed that more than half of the doses administered over the last few weeks were inoculated in rural areas. Union health secretary Rajesh Bhushan informed that the new Delta Plus variant has been found in 16 of the 22 cases including Ratnagiri and Jalgaon in Maharashtra including Kerala and Madhya Pradesh. As India continues to battle the virus, the health ministry announced that in 553 districts in the country the coronavirus positivity rate has dipped to less than 5 per cent. The ministry said that over 2.14 crore coronavirus vaccine doses were still available with the states and Union Territories and over 33,80,590 vaccine doses are in the pipeline. On Monday, the Indian government had started the "Free Vaccination For All campaign". According to the revised guidelines, vaccine doses will be provided free of cost by the Centre based on criteria such as state's population, disease burden and vaccination progress. All adults above 18 years will be eligible for the free jabs.

Covaxin has shown 77.8 per cent efficacy against virus: Report

drugs-controller-general-of-india

Drugs Controller General Of India, News on Drugs Controller General Of India, stories on Drugs Controller General Of India, articles on Drugs Controller General Of India, Drugs Controller General Of India stories at Wion, Drugs Controller General Of India news, Drugs Controller General Of India latest news

drugs controller-general-of-india

Corbevax becomes first vaccine in India to get DCGI approval for heterologous COVID-19 booster shot

Novavax says its COVID-19 vaccine gets India authorisation for children aged 12 to 17 years

Covaxin has shown 77.8 per cent efficacy against virus: Report